The effects of canola and olive oils consumption compared to sunflower oil, on lipid profile and hepatic steatosis in women with polycystic ovarian syndrome: a randomized controlled trial
Open accessThe DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
Background: Polycystic Ovarian Syndrome (PCOS) is one of the most common endocrinopathies and metabolic disorders in women during their reproductive years. It is often associated with dyslipidemia and other risk factors of cardiovascular diseases (CVD). This study was aimed to evaluate dietary intervention effects with canola and olive oils compared to sunflower oil on lipid profile and fatty liver severity among women with PCOS. Method: This study was a 10-week intervention including 72 women with PCOS. Patients were randomly assigned to three groups for receiving 25 g/day canola, olive, or sunflower oils for 10 weeks. The primary and secondary outcomes were to assess changes in lipid profile and in fatty liver severity, respectively. Result: At the end of the study, 72 patients with a mean age of 29.31 were analysed. Canola oil consumption resulted in a significant reduction in serum levels of TG ( P = 0.002) and TC/HDL ( P = 0.021), LDL/HDL ( P = 0.047), and TG/HDL ( P = 0.001) ratios, however, there was no significant reduction in lipid profile following olive oil consumption. Canola ( P < 0.001) and olive oils ( P = 0.005) could significantly reduce the fatty liver grade. Moreover, HOMA-IR in both canola ( P < 0.001) and olive ( P = 0.004) groups was significantly decreased. Conclusion: In total, compared to olive and sunflower oils, significant improvements in lipid profile, liver function, and HOMA-IR were observed following canola oil consumption in women with PCOS. Trial registration: IR.MUI.RESEARCH.REC.1397.315. Registered 30 JUNE 2019 - Retrospectively registered, https://www.irct.ir/trial/38684
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Use and Abuse of HOMA Modeling
Wallace, T. M., Levy, J. C., & Matthews, D. R. (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1487 · Cited by 5,114
Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6661 · Cited by 3,931 · cited 1×
“Then, HOMA-IR was calculated using the following formula for each participant [60, 61]: HOMA-IR = (FSG × FSI) / 405.”
MethodMensink, R. P., Zock, P. L., Kester, A. D., & Katan, M. B. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.5.1146 · Cited by 2,811 · cited 10×
“Serum concentrations of TG, HDL-c, LDL-c, and total cholesterol were measured using an enzymatic colorimetric method (Pars Azmoon, Tehran, Iran).”
BackgroundInfluentialPolycystic Ovary Syndrome: Definition, Aetiology, Diagnosis and Treatment
Escobar-Morreale, H. F. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2018.24 · Cited by 2,083
Profound Peripheral Insulin Resistance, Independent of Obesity, in Polycystic Ovary Syndrome
Dunaif, A., Segal, K. R., Futterweit, W., & Dobrjansky, A. (1989) · Diabetes · doi:10.2337/diab.38.9.1165 · Cited by 1,967
Teede, H., Deeks, A., & Moran, L. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-41 · Cited by 1,565 · cited 1×
“Overall, these hormonal imbalances can progress to metabolic and cardiovascular diseases [55].”
n-3 fatty acids and serum lipoproteins: human studies
Harris, W. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.5.1645s · Cited by 1,243
Mozaffarian, D., Micha, R., & Wallace, S. (2010) · PLoS Medicine · doi:10.1371/journal.pmed.1000252 · Cited by 1,215 · cited 1×
“Replacing saturated fatty acids (SFAs) with polyunsaturated fatty acids (PUFAs) can reduce insulin resistance resulting in improved lipid profile [16, 17].”
BackgroundLaaksonen, D. E., Niskanen, L., Punnonen, K., Nyyssönen, K., Tuomainen, T.-P., Valkonen, V.-P., Salonen, R., & Salonen, J. T. (2004) · Diabetes Care · doi:10.2337/diacare.27.5.1036 · Cited by 920 · cited 1×
“Low serum SHBG concentrations in overweight individuals are a biomarker for metabolic syndrome [45, 46] and are predictive of type 2 diabetes (T2D) [47, 48] and CVD risk [49–51].”
BackgroundBurdge, G. C., & Wootton, S. A. (2002) · British Journal Of Nutrition · doi:10.1079/bjn2002689 · Cited by 812 · cited 1×
“Previous studies showed an inverse relationship between the menopausal status of women and the age of female participants with the change in plasma EPA content after olive oil supplementation [24, 25].”
BackgroundSex hormone-binding globulin and risk of type 2 diabetes in women and men
Ding, E. L., Song, Y., Manson, J. E., Hunter, D. J., Lee, C. C., Rifai, N., Buring, J. E., Gaziano, J. M., & Liu, S. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0804381 · Cited by 726 · cited 2×
“Low serum SHBG concentrations in overweight individuals are a biomarker for metabolic syndrome [45, 46] and are predictive of type 2 diabetes (T2D) [47, 48] and CVD risk [49–51].”
BackgroundARAYA, J., RODRIGO, R., VIDELA, L. A., THIELEMANN, L., ORELLANA, M., PETTINELLI, P., & PONIACHIK, J. (2004) · Clinical Science · doi:10.1042/cs20030326 · Cited by 700
Burdge, G. C., Jones, A. E., & Wootton, S. A. (2002) · British Journal Of Nutrition · doi:10.1079/bjn2002662 · Cited by 598
Ascaso, J. F., Pardo, S., Real, J. T., Lorente, R. I., Priego, A., & Carmena, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.12.3320 · Cited by 490
Low serum testosterone and sex-hormone-binding-globulin in massively obese men
GLASS, A. R., SWERDLOFF, R. S., BRAY, G. A., DAHMS, W. T., & ATKINSON, R. L. (1977) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-45-6-1211 · Cited by 430 · cited 1×
“BMI is considered the main determinant of circulating SHBG concentrations, and a negative correlation between BMI and SHBG plasma levels was consistently reported [42].”
BackgroundClinical and psychological correlates of quality-of-life in polycystic ovary syndrome
Hahn, S., Janssen, O. E., Tan, S., Pleger, K., Mann, K., Schedlowski, M., Kimmig, R., Benson, S., Balamitsa, E., & Elsenbruch, S. (2005) · European Journal of Endocrinology · doi:10.1530/eje.1.02024 · Cited by 387
Ding, T., Hardiman, P. J., Petersen, I., Wang, F.-F., Qu, F., & Baio, G. (2017) · Oncotarget · doi:10.18632/oncotarget.19180 · Cited by 336 · cited 1×
“Regarding the study of Ding et al. (2017), in women with reproductive age, the PCOS prevalence was estimated from 5 to 18% which is higher in obese and diabetic women [3].”
BackgroundPPARs, Obesity, and Inflammation
Stienstra, R., Duval, C., Müller, M., & Kersten, S. (2007) · PPAR Research · doi:10.1155/2007/95974 · Cited by 287
Lindstedt, G., Lundberg, P.-A., Lapidus, L., Lundgren, H., Bengtsson, C., & Björntorp, P. (1991) · Diabetes · doi:10.2337/diab.40.1.123 · Cited by 252
The management of insulin resistance in polycystic ovary syndrome
Teede, H. J., Hutchison, S. K., & Zoungas, S. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.001 · Cited by 135 · cited 1×
“Furthermore, an ongoing debate is present whether IR in PCOS is due to obesity alone or obesity aggravates IR intrinsic to PCOS [39, 40].”
BackgroundWild, R. A. (2012) · Steroids · doi:10.1016/j.steroids.2011.12.002 · Cited by 117 · cited 2×
“In a meta-analysis, researchers reported that women with PCOS have 26mg/dL higher triglycerides, lower HDL-cholesterol, and higher non-HDL-cholesterol levels compared with their non-PCOS counterparts [12].”
BackgroundJenkins, D. J. A., Kendall, C. W. C., Vuksan, V., Faulkner, D., Augustin, L. S. A., Mitchell, S., Ireland, C., Srichaikul, K., Mirrahimi, A., Chiavaroli, L., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2990 · Cited by 91 · cited 1×
“Dietary ingredients, especially the type and amount of fats, are important in liver fat deposition, which is responsible for 15% of liver fat content [31].”
BackgroundPhelan, N., O’Connor, A., Kyaw Tun, T., Correia, N., Boran, G., Roche, H. M., & Gibney, J. (2011) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.110.005538 · Cited by 89
Rivellese, A. A., Giacco, R., Annuzzi, G., De Natale, C., Patti, L., Di Marino, L., Minerva, V., Costabile, G., Santangelo, C., Masella, R., et al. (2008) · Clinical Nutrition · doi:10.1016/j.clnu.2007.07.005 · Cited by 56 · cited 2×
“The faster oxidation of MUFAs can clarify the positive effects of olive oil on hepatic fat content than SFA in the postprandial phase [86].”
BackgroundComparison of Dietary Intake between Polycystic Ovary Syndrome Women and Controls
Shishehgar, F., Ramezani Tehrani, F., Mirmiran, P., Hajian, S., Baghestani, A. R., & Moslehi, N. (2016) · Global Journal of Health Science · doi:10.5539/gjhs.v8n9p302 · Cited by 49 · cited 1×
“Studies showed that dietary fatty acid patterns could exert important effects on PCOS related complications, including obesity, imbalanced glycemic and hormonal homeostasis, inflammation, and dysregulation of adipokine production [14, 15].”
Background
Cited by
The Role of Lifestyle Interventions in PCOS Management: A Systematic Review
Gautam, R., Maan, P., Jyoti, A., Kumar, A., Malhotra, N., & Arora, T. (2025) · Nutrients · doi:10.3390/nu17020310 · Cited by 115
Pourrajab, B., Sharifi-Zahabi, E., Soltani, S., Shahinfar, H., & Shidfar, F. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2100314 · Cited by 15
Exploring the Role of Extra Virgin Olive Oil (EVOO) in MASLD: Evidence from Human Consumption
Bernardino, M., Tiribelli, C., & Rosso, N. (2025) · Nutrients · doi:10.3390/nu17182932 · Cited by 7
Takhttavous, A., Rostampour, K., Gerami, S., & Mohammadi-Sartang, M. (2026) · Nutrition Reviews · doi:10.1093/nutrit/nuaf099 · Cited by 1
Metadata
- Authors
- Yahay, M., Heidari, Z., Allameh, Z., & Amani, R.
- Venue
- Lipids in Health and Disease
- Published
- 2021-01-29
- Volume
- 20
- Issue
- 1
- Pages
- 7-7
- ISSN
- 1476-511X (ISSN-L)
- OpenAlex
- W3121658675
- Cited by
- 48
- References
- 26
- FWCI
- 6.69
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.